|
 |
Peginterferon alfa-2bThis page contains recent news articles, when available, and an overview of Peginterferon alfa-2b but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Peginterferon alfa-2b (when available) Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R. For treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma Mechanism Of Action: Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta. News Articles on Peginterferon alfa-2b SILENCE THERAPEUTICS PLC - Acquisition - Dec 16, 2009 ...oncology therapeutics including Doxil(R) (doxorubicin HCL liposome injection), PegIntron(R) (Peginterferon alfa-2b) and Vectibix(R) (panitumumab). ... Trading Markets (press release) Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518 ... - Nov 2, 2009 Once-Daily Narlaprevir (SCH 900518) in Combination with Peginterferon alfa-2b/Ribavirin for Treatment-Naive Patients with Genotype-1 Chronic Hepatitis C: ... Reuters Results from two Canadian studies confirm sustained viral response rates seen ... - Nov 2, 2009 ...consistent with the 40 per cent SVR attained with approved peginterferon alfa-2B/ribavirin (PEGETRON) therapy in the recent United States-based IDEAL ... Canada NewsWire (press release) Successful Treatment with Peginterferon alfa-2b of HBeAg-positive HBV... - Mar 2, 2006 Correspondence: Harry LA Janssen, MD, PhD, Department of Gastroenterology and Hepatology, Erasmus Medical Center, Dr. Molewaterplein 40, Room Ca 326, ... Nature.com Roche presents favorable data on hepatitis drug Pegasys - Apr 28, 2008 By Zurich Bureau. ZURICH (MarketWatch) -- Swiss drug company Roche Holding AG (NQB:RHHB.Y) said Monday studies of its hepatitis treatment Pegasys shows it ... MarketWatch Learn about Peginterferon alfa-2b from Consumer Reports Health. - Jan 7, 2005 Peginterferon alfa-2b may cause or worsen the following conditions that may be serious or cause ... Full Alert. Peginterferon alfa-2b is used alone or in ... consumerreports.org Hepatitis C therapy peginterferon alfa-2b shows promise - Apr 24, 2008 The hepatitis C therapy peginterferon alfa-2b, when given as low-dose maintenance therapy, can prevent disease progression in certain patients who failed ... News-Medical.net Peginterferon alfa-2b produced sustained responses in patients with … - Jan 7, 2005 Results from a large international clinical study reported in this week's issue of The Lancet showed that peginterferon alfa-2b produced sustained responses ... News-Medical.net Examining Gene Expression, Drug Compounds And Liver … - May 20, 2007 Hepatitis C not only affects more than 3.9 million Americans, but continues to impact and influence the occurrence of related inflammatory conditions. ... Medical News Today - Medical News Today (press release) Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma ... - Jul 11, 2008 KENILWORTH, NJ, July 11 /PRNewswire-FirstCall/ -- Today, Schering-Plough and the EORTC announced that long-term treatment with pegylated interferon alfa-2b ... RedOrbit How to take Peginterferon alfa-2b from Consumer Reports Health. - Jan 7, 2005 Peginterferon alfa-2b may cause or worsen the following conditions that may be serious or cause ... Full Alert. tell your doctor and pharmacist if you are ... consumerreports.org Results of Peginterferon Alfa-2b and Ribavirin Study in Retreating … - Oct 30, 2006 BOSTON, MA -- October 30, 2006 -- Schering-Plough today reported data from EPIC3, a large ongoing clinical study, showing that retreatment with ... DG News PegIntron(R) (peginterferon alfa-2b) Clinical Studies in Hepatitis to... - Apr 7, 2005 Schering-Plough's PegIntron(R) (peginterferon alfa-2b), used in combination therapy with Rebetol(R) (ribavirin), is proven effective in treating patients ... Free with registration - PR Newswire Europe - AccessMyLibrary.com … Review for Schering-Plough's Peginterferon Alfa-2b for the... - Jan 31, 2008 FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research PegInterferon-alfa-2b with Ribavirin Shows Promise - May 3, 2005 By American Association for the Study of Liver Diseases (AASLD), [RxPG] More than half of 61 children infected with chronic hepatitis C achieved a sustained ... RxPG NEWS Press Release: Human Genome Sciences Announces Full Presentation … - Nov 5, 2007 Human Genome Sciences Announces Full Presentation of Quality-of-Life Results From Phase 2b Trial of Albuferon(R) for Hepatitis C. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research peginterferon alfa-2b Schering Plough clinical data (hepatitis C). - Dec 11, 2006 On 27 October 2006 Shering-Plough reported further data from EPIC3, a large multicenter clinical study in chronic HCV patients who failed previous ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones … First Study Showing Peginterferon Alfa-2b Effective as Monotherapy... - Jan 7, 2005 The Lancet Publishes First Study Showing Peginterferon Alfa-2b Effective as Monotherapy in the Treatment of Chronic Hepatitis B. ... find PR Newswire Europe ... Pay-Per-View - PR Newswire Europe - HighBeam Research Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations … - Oct 30, 2007 KENILWORTH, NJ, Oct. 30 /PRNewswire-FirstCall/ -- Leading researchers will present 68 data presentations involving Schering-Plough's hepatitis products, ... RedOrbit Press Release: New Data from Largest US Hepatitis C Trial Provide … - Oct 30, 2006 New Data from Largest US Hepatitis C Trial Provide Insights Into Optimizing Treatment for Patient Populations Traditionally Considered Difficult to Treat. Pay-Per-View - PR Newswire - HighBeam Research … Review for Schering-Plough's Peginterferon Alfa-2b for the... - Feb 1, 2008 FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma. ... find BIOTECH ... Pay-Per-View - BIOTECH Patent News - HighBeam Research … B Therapy; Study shows peginterferon alfa-2b effective monotherapy... - Feb 8, 2005 2005 FEB 8 - (NewsRx.com & NewsRx.net) -- Results from a large international clinical study reported in The Lancet showed that peginterferon alfa-2b ... Pay-Per-View - Science Letter - Factiva, from Dow Jones Press Release: Human Genome Sciences Announces Presentation at … - Nov 5, 2007 Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Customizing treatment to patient populations - Aug 10, 2006 Combination treatment with pegylated interferon plus ribavirin is the most effective therapy for patients with chronic hepatitis C virus (HCV); however, ... Nature.com Press Release: Three Studies Presented at 43rd EASL Showed Higher … - Apr 26, 2008 Three Studies Presented at 43rd EASL Showed Higher SVR for PEGASYS(R) (Peginterferon Alfa-2a) Plus Ribavirin Than Peginterferon Alfa-2b Plus Ribavirin in ... Pay-Per-View - PR Newswire - HighBeam Research … Center; Study shows peginterferon alfa-2b effective monotherapy... - Feb 9, 2005 2005 FEB 9 - (NewsRx.com & NewsRx.net) -- Results from a large international clinical study reported in The Lancet showed that peginterferon alfa-2b ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones Similar Efficacy Shown For Pegylated Interferon Alfa-2b, Pegylated … - Nov 7, 2007 By Maria Bishop. BOSTON, MA -- November 7, 2007 -- There is no difference in sustained viral response (SVR) rates between patients with hepatitis C virus ... DG News … B Therapy; Study shows peginterferon alfa-2b effective monotherapy... - Feb 12, 2005 2005 FEB 12 - (NewsRx.com & NewsRx.net) -- Results from a large international clinical study reported in The Lancet showed that peginterferon alfa-2b ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Press Release: MIGENIX Receives Approval for MX-3253 Phase II … - May 16, 2006 Article: Peginterferon alfa-2b (PegIntron) has to be given ... PR Newswire; July 28, 2003 ; 700+ words ... ... prescribed once weekly dosing schedule of ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Three Studies Presented at 43rd EASL Strongly Indicate... - Apr 26, 2008 Three Studies Presented at 43rd EASL Strongly Indicate Better Efficacy for PEGASYS in Curing Hepatitis C.(Clinical report) from PR Newswire Europe. Pay-Per-View - PR Newswire Europe - HighBeam Research Press Release: Roche Driving PROGRESS in Treatment of Difficult-to- … - Mar 14, 2007 Roche Driving PROGRESS in Treatment of Difficult-to-Cure Hepatitis C Patients With New PEGASYS (R) (peginterferon alfa-2a (40KD)) and COPEGUS(R) (ribavirin) ... Pay-Per-View - PR Newswire Europe - HighBeam Research PegIntron(R) (peginterferon alfa-2b) Clinical Studies in Hepatitis to... - Apr 7, 2005 PegIntron(R) (peginterferon alfa-2b) Clinical Studies in Hepatitis to be Presented at 40th Annual Meeting of the European Association for the Study of the ... Pay-Per-View - PR Newswire Europe - HighBeam Research Press Release: MIGENIX Reports First Quarter Fiscal Year 2007... - Sep 15, 2006 MIGENIX Reports First Quarter Fiscal Year 2007 Financial Results. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research … labeling changes for peginterferon alfa-2b (PegIntron, Schering... - May 1, 2008 FDA approved labeling changes for peginterferon alfa-2b (PegIntron, Schering-Plough) and ribavirin (Rebetul, Schering-Plough) as combination therapy for the ... $9.94 - Formulary - Alacra Store Press Release: Schering-Plough Highlights PEGINTRON(TM) Clinical … - Oct 30, 2007 Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: MIGENIX Completes Enrollment of Celgosivir (MX-3253) … - Jun 15, 2006 MIGENIX Completes Enrollment of Celgosivir (MX-3253) Phase IIb HCV Combination Study. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Press Release: Potential New Oral Treatment May Revolutionise … - Apr 26, 2008 Potential New Oral Treatment May Revolutionise Management of Deadly Hepatitis C Virus. from PR Newswire Europe. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire Europe - HighBeam Research … Shows 12 Weeks of Peginterferon Alfa-2b and Ribavirin Combination ... - Jun 22, 2005 SAN GIOVANNI ROTONDO, Italy, June 22 /PRNewswire-FirstCall/ -- Results of a new study published in the current issue of the New England Journal of Medicine ... $4.95 - PR Newswire - ECNext International Approvals: DCVax-Brain, PegIntron/Rebetol, Revlimid - Jul 16, 2007 July 16, 2007 — The Swiss Institute of Public Health has approved the world's first brain cancer vaccine. The European Commission (EC) has approved an ... Medscape Press Release: Customising Treatment With PEGASYS(R) Plus … - Oct 27, 2006 Customising Treatment With PEGASYS(R) Plus COPEGUS(R) Improves Chances for Cure in Hepatitis C.(Clinical report) from PR Newswire Europe. Pay-Per-View - PR Newswire Europe - HighBeam Research Hepatitis C Therapy; Peginterferon alfa-2b benefits patients diagnosed... - Apr 30, 2005 2005 APR 30 - (NewsRx.com) -- Peginterferon alfa-2b benefits patients diagnosed with acute hepatitis C. According to a study from Italy, "acute hepatitis C ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Press Release: European Commission Approval of New Indication for … - Dec 4, 2008 European Commission Approval of New Indication for Roche's Pegasys(R) (peginterferon alfa-2a) Offers Hepatitis C Patients a Second Chance for a Cure. from ... Pay-Per-View - PR Newswire Europe - HighBeam Research Early and Accurate Prediction of Peg-IFNs/Ribavirin Therapy Outcome... - Oct 25, 2007 A novel biomathematical model that analyzes the combined alanine transaminase (ALT) and viral-load kinetics during the first month of pegylated interferon ... Nature.com New Data from Largest US Hepatitis C Trial Provide Insights Into … - Oct 31, 2006 BOSTON, MA -- October 31, 2006 -- New data from the WIN-R trial, the largest hepatitis C study ever conducted in US patients, provide important insights ... DG News … Shows 12 Weeks of Peginterferon Alfa-2b and Ribavirin Combination ... - Jun 22, 2005 Study Shows 12 Weeks of Peginterferon Alfa-2b and Ribavirin Combination Therapy as Effective as 24 Weeks in Certain Hepatitis C Patients With Genotype 2 or ... Pay-Per-View - PR Newswire Europe - HighBeam Research Press Release: European Commission Approval of New Indication for … - Dec 4, 2008 European Commission Approval of New Indication for Roche's Pegasys(R) (peginterferon alfa-2a) Offers Hepatitis C Patients a Second Chance for a Cure. from ... Pay-Per-View - PR Newswire Europe - HighBeam Research New Clinical Study Results Indicate Higher Early Virologic Response... - Apr 11, 2007 VANCOUVER and SAN DIEGO, CA, April 11 /PRNewswire-FirstCall/ -- MIGENIX Inc. (TSX: MGI, OTC: MGIFF), a clinical-stage developer of drugs for infectious ... Free with registration - PR Newswire - AccessMyLibrary.com MIGENIX Receives Approval for MX-3253 Phase II Combination Viral … - May 16, 2006 VANCOUVER and SAN DIEGO, May 16 /PRNewswire-FirstCall/ -- MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and ... Free with registration - PR Newswire - AccessMyLibrary.com Hepatitis C Therapy; Peginterferon alfa-2b benefits patients diagnosed... - Apr 26, 2005 According to a study from Italy, "acute hepatitis C often progresses to chronic infection (70%). In this clinical study, we evaluated if early treatment ... Pay-Per-View - Virus Weekly - Factiva, from Dow Jones What is the safe duration of therapy for patients infected with HCV … - Oct 15, 2008 Until prospective trials are conducted, 48 weeks of combination therapy with pegylated interferon plus ribavirin should be used to treat patients with ... Nature.com Data on PEG-INTRON(R) and REBETOL(R) Combination Therapy in … - May 12, 2005 KENILWORTH, NJ, May 12 /PRNewswire-FirstCall/ -- Important new data on PEG-INTRON(R) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination ... RedOrbit MIGENIX Reports Fourth Quarter and Fiscal Year 2006 Financial Results. - Jul 13, 2006 VANCOUVER, BC, and SAN DIEGO, CA, July 13 /PRNewswire-FirstCall/ -- MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious ... Free with registration - PR Newswire - AccessMyLibrary.com … Shows 12 Weeks of Peginterferon Alfa-2b and Ribavirin Combination ... - Jun 22, 2005 Study Shows 12 Weeks of Peginterferon Alfa-2b and Ribavirin Combination Therapy as Effective as 24 Weeks in Certain Hepatitis C Patients With Genotype 2 or ... Pay-Per-View - PR Newswire - HighBeam Research Meeting Highlights From The Committee For Medicinal Products For … - Apr 23, 2007 The European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a ... Medical News Today - Medical News Today (press release) Schering-Plough Presents Positive Results From Phase III Melanoma … - Jul 14, 2008 Schering-Plough and the European Organization for the Research and Treatment of Cancer have announced positive results from a randomized Phase III melanoma ... RedOrbit Press Release: Data on PEG-INTRON(R) and REBETOL(R) Combination … - May 12, 2005 Data on PEG-INTRON(R) and REBETOL(R) Combination Therapy in Diverse Patient Populations to Be Presented at 2005 Digestive Disease Week (DDW) Meeting. from ... Pay-Per-View - PR Newswire - HighBeam Research Schering-Plough Highlights Hepatitis C Presentations at the American ... - Oct 24, 2006 KENILWORTH, NJ -- More than 50 data presentations involving Schering-Plough's hepatitis products, including PEG- INTRON® (peginterferon alfa-2b) and ... EndoNurse Data on Schering-Plough's Oral HCV Protease Inhibitor to be Presented... - Nov 7, 2005 KENILWORTH, New Jersey, November 7/PRNewswire/ -- Important new data on Schering-Plough's investigational oral protease inhibitor in development for ... biotech-intelligence.com Bartlett HIV/AIDS Review: March 15, 2005: HIV and Hepatitis - Mar 15, 2005 Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs. standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected ... Medscape MIGENIX Completes Enrollment of Celgosivir (MX-3253) Phase IIb HCV … - Jun 15, 2006 VANCOUVER/SAN DIEGO, June 15 /PRNewswire-FirstCall/ -- MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and ... Free with registration - PR Newswire - AccessMyLibrary.com Press Release: Telenor Resists Alfa's Attempt to Gain Control of … - Jun 7, 2005 Telenor Resists Alfa's Attempt to Gain Control of VimpelCom. from PR Newswire Europe. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire Europe - HighBeam Research Summary and Introduction - Sep 12, 2005 Both absolute viral load and log decline in viral load from baseline were found clinically useful in predicting sustained virological response and lack of ... Medscape Press Release: Boceprevir Phase II Study Showed High Rate of … - Nov 1, 2008 Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients. from PR ... Pay-Per-View - PR Newswire - HighBeam Research GI Journal Scan Dec 2004 - Jan 18, 2005 Journal Scan is the clinician's guide to the latest clinical research findings in Gastroenterology, Hepatology, The American Journal of Gastroenterology, ... Medscape Approvals: Herceptin, Reyataz, and Peg-Intron - May 21, 2007 May 21, 2007 — The European Commission has approved a new indication for trastuzumab infusion, allowing its use with hormonal therapy in the treatment of ... Medscape New paradigms in the management of hepatitis C virus co-infections - Jul 31, 2006 Liver disease has emerged as a major contributor to morbidity and mortality in patients with HIV infection. Hepatitis C virus (HCV) infection is a key ... Nature.com Treatment of Chronic Hepatitis C Virus in African Americans With … - May 12, 2006 Previous studies have documented that sustained virologic response (SVR) is significantly reduced in African Americans with chronic HCV genotype 1 following ... Nature.com Press Release: Milliman Releases MG-ALFA(R) Version 6.6. - PR … - Jun 16, 2008 Milliman Releases MG-ALFA(R) Version 6.6. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Summary and Introduction - Mar 1, 2006 In therapy with standard interferon and ribavirin, five independent risk factors (RF) were predictive of relapse. The aim was to prospectively validate an a ... Medscape Long-Term Follow-Up of Previous Hepatitis C Virus Positive … - Dec 14, 2005 Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ... Peginterferon alfa- 2b and ribavirin for treatment-refractory chronic ... Nature.com An overview of European Association for the Study of Liver 41st... - May 22, 2006 Hepatitis C patients who have no sign of virus 24 weeks after completing treatment (sustained virological response) can be told they are cured, ... $4.95 - Pharma Marketletter - ECNext Press Release: Shorter Course of PEG-INTRON(R) and REBETOL(R) … - Oct 5, 2005 Shorter Course of PEG-INTRON(R) and REBETOL(R) Combination Therapy Approved in European Union for Certain Hepatitis C Patients With Genotype 1 and Low Viral ... Pay-Per-View - PR Newswire - HighBeam Research Peginterferon Plus Ribavirin May Be Helpful in Pediatric HCV Infection - May 10, 2005 May 10, 2005 — Combination treatment with peginterferon alfa-2b and ribavirin is well tolerated and offers encouraging results for children and adolescents ... Medscape Celgosivir Combination Therapy Demonstrates Positive Clinical Benefit... - Nov 6, 2006 VANCOUVER, BC and SAN DIEGO, CA, Nov. 6 /PRNewswire-FirstCall/ -- MIGENIX Inc. (TSX: MGI, OTC: MGIFF), a clinical-stage developer of drugs for infectious ... $4.95 - PR Newswire - ECNext Ribavirin (Systemic). - Oct 27, 2005 Ribavirin (rye-ba-VYE-rin) is used to treat severe virus pneumonia in infants and young children. It is given by oral inhalation (breathing in the medicine ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Ribavirin (Systemic). - Feb 1, 2006 Interferon alfa-2b and peginterferon alfa-2b are used to treat a variety of tumors and viruses including the hepatitis C virus. ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Albuferon in Phase 2b Trial for the Treatment of Chronic Hepatitis C - Jun 2, 2005 For more information about Albuferon, see http://www.hgsi.com/products/albuferon.html. Health professionals interested in more information about trials ... RxPG NEWS An overview of European Association for the Study of Liver 41st... - May 15, 2006 Hepatitis C patients who have no sign of virus 24 weeks after completing treatment (sustained virological response) can be told they are cured, ... Pay-Per-View - Pharma Marketletter - Factiva, from Dow Jones MIGENIX Reports First Quarter Fiscal Year 2007 Financial Results. - Sep 15, 2006 VANCOUVER and SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and ... $4.95 - PR Newswire - ECNext New Study Shows That Pegasys Regimen Provides Higher Cure Rates … - Jan 11, 2008 BASEL, Switzerland, November 1 /PRNewswire/ -- A new, independently-conducted study being presented at AASLD shows that PEGASYS(R) (peginterferon alfa-2a ... ITNews New Study Shows That Pegasys Regimen Provides Higher Cure Rates … - Nov 2, 2008 A new, independently-conducted study being presented at AASLD shows that PEGASYS(R) (peginterferon alfa-2a (40KD)) regimens result in higher cure rates for ... Medical News Today - Medical News Today (press release) Schering-Plough Addresses Major Milestones and Challenges in … - Apr 11, 2007 KENILWORTH, NJ, April 11 /PRNewswire-FirstCall/ -- Schering-Plough Corporation reaffirms its commitment to advancing the science and treatment of chronic ... Free with registration - PR Newswire - AccessMyLibrary.com MIGENIX Initiates Enrollment in Phase IIb Hepatitis C Clinical Study... - Nov 22, 2005 VANCOUVER and SAN DIEGO, Nov. 22 /PRNewswire-FirstCall/ -- MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and ... biotech-intelligence.com Schering-Plough Highlights PEGINTRON(TM) And Boceprevir Data … - Apr 18, 2008 Colchicine versus peginterferon alfa 2b long term therapy: results of the 4 year COPILOT trial. Afdhal, NH et al. General Session 1, Thursday, April 24, ... Medical News Today - Medical News Today (press release) MIGENIX Reports Second Quarter Fiscal Year 2007 Financial Results. - Dec 13, 2006 VANCOUVER and SAN DIEGO, Dec. 13 /PRNewswire-FirstCall/ -- MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and ... Free with registration - PR Newswire - AccessMyLibrary.com Schering-Plough Highlights PEGINTRON(TM) And Boceprevir Hepatitis C … - May 16, 2008 Schering-Plough Corporation (NYSE: SGP), a leader in advancing the science and treatment of chronic hepatitis C virus (HCV) infection, announced that data ... Medical News Today - Medical News Today (press release) Press Release: MIGENIX receives approval to initiate MX-3253 Phase... - Aug 11, 2005 MIGENIX receives approval to initiate MX-3253 Phase IIb combination study in HCV non-responders. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Experimental Drug Combo Tested in Tough-to-Treat Patients - Apr 27, 2005 ...by John C. Martin. An experimental combination of medications may be effective in a certain group of people with hepatitis C (HCV) who historically have ... Hepatitis Neighborhood Press Release: Roche responds to announcement of 'IDEAL' hepatitis C ... - Jan 14, 2008 Roche responds to announcement of 'IDEAL' hepatitis C trial results. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research New data show SP's PegIntron to be an effective monotherapy for … - Jan 17, 2005 Results from a large international clinical study, organized and sponsored by the Foundation for Liver Research and published in the January 8 issue of The ... Pay-Per-View - Pharma Marketletter - Factiva, from Dow Jones Treating children with chronic hepatitis C - Mar 5, 2005 More than half of 61 children infected with chronic hepatitis C achieved a sustained viral response after treatment with peginterferon-alfa-2b and ribavirin ... innovations report - Innovations-Report About 60 Clinical Studies Regarding Schering-Plough's Oncology … - May 31, 2008 Schering-Plough Corporation (NYSE: SGP) announced that about 80 posters, poster discussions, and oral presentations from about 60 clinical studies relating ... Medical News Today - Medical News Today (press release) Hepatitis C Virus/HIV Coinfection - Apr 13, 2005 Data from 4 major trials evaluating the treatment of hepatitis C virus (HCV) in HIV-HCV coinfection make it clear that many HIV-infected individuals can be ... Medscape Combining Peginterferon With Weight-Based Ribavirin Increases … - Mar 27, 2008 Peginterferon alfa-2b and Weight-Based or Flat-Dose Ribavirin in Chronic ... Peginterferon alfa-2b plus Ribavirin Compared with Interferon alfa-2b plus ... DG News Press Release: Celgosivir Combination Therapy Demonstrates Positive … - Nov 6, 2006 Celgosivir Combination Therapy Demonstrates Positive Clinical Benefit in Chronic Hepatitis C Non-Responder Patients. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Chronic Hepatitis C in Latinos: Natural History, Treatment Eligibility... - Feb 27, 2005 The natural history of chronic hepatitis C and treatment response are different between blacks and Caucasians, but little comparable data is available about ... Nature.com Associations between the human MHC and sustained virologic response … - Apr 17, 2008 Correspondence: Dr LJ Yee, University of Pittsburgh, A511 Crabtree Hall, 130 DeSoto Street, Pittsburgh, PA 15261, USA. E-mail: YeeL@edc.pitt.edu ... Nature.com Press Release: New Study Shows That Pegasys Regimen Provides … - Nov 1, 2008 New Study Shows That Pegasys Regimen Provides Higher Cure Rates for Hepatitis C Patients.(Clinical report) from PR Newswire Europe. Pay-Per-View - PR Newswire Europe - HighBeam Research Hepatitis C: reviewing the options.(Letter to the editor) - Jul 4, 2006 Tom Wong and Samuel Lee (1) mention some extrahepatic manifestations of infection with hepatitis C virus (HCV), but they do not discuss the urticarias. ... Free with registration - CMAJ: Canadian Medical Association... - AccessMyLibrary.com Results of PEG-INTRON(R) and REBETOL(R) Study in Retreating … - Oct 27, 2006 BOSTON, Oct. 27 /PRNewswire-FirstCall/ -- Schering-Plough today reported data from EPIC3, a large ongoing clinical study, showing that retreatment with ... RedOrbit WIN-R Study Demonstrates Efficacy of Shorter PEG-Intron and Rebetol … - Apr 28, 2006 VIENNA, AUSTRIA -- April 28, 2006 -- For patients infected with hepatitis C virus (HCV) genotype 2 or 3, a shorter, 24-week course of therapy with ... DG News MIGENIX receives approval to initiate MX-3253 Phase IIb combination … - Aug 11, 2005 An agreement was completed in July with Schering-Plough for (a) the supply of PEGETRON(TM) (peginterferon alfa-2b powder for solution plus ribavirin 200 mg ... $4.95 - PR Newswire - ECNext Investigational Agent Effectively Attacks Hepatitis C Virus From New ... - May 28, 2007 By Em Brown. WASHINGTON, DC -- May 28, 2007 -- Celgozivir a novel agent that inhibits the alpha-glucosidase I enzyme, prevents the hepatitis C virus (HCV) ... DG News Brand Names/Synonyms: Peginterferon alfa-2b is also known by the following brand names and/or synonymsInterferon alpha-2 precursor;Interferon alpha-A;LeIF A; PEG-Intron Drug Category: Peginterferon alfa-2b is categorized under the following by the FDA: Antiviral Agents; Immunomodulatory Agents; Antineoplastic Agents; interferons (08:18.20) Dosage Forms: POWDER FOR SOLUTION Absorption: Not Available Interactions: Not Available Chemical IUPAC Name: PEGylated human interferon alpha 2b |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
